Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action
- 1 June 2000
- journal article
- Published by Springer Nature in Neurotoxicity Research
- Vol. 2 (2-3) , 85-97
- https://doi.org/10.1007/bf03033787
Abstract
The involvement of glutamate mediated neurotoxicity in the pathogenesis of Alzheimer’s disease is finding increasingly more acceptance in the scientific community. Central to this hypothesis is the assumption that in particular glutamate receptors of the N-methyl-D-aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner. Such continuous mild activation leads under chronic conditions to neuronal damage. Moreover, one should consider that impairment of plasticity (learning) may result not only from neuronal damage per se but also from continuous activation of NMDA receptors. To investigate this possibility we tested whether over-activation of NMDA receptors using either non-toxic doses/concentrations of a direct NMDA agonist or through an indirect approach — decrease in magnesium concentration ö produces deficits in plasticity. In fact NMDA bothin vivo (passive avoidance test) andin vitro (LTP in CA1 region) impaired learning and synaptic plasticity. Under these conditions mem-antine which is an uncompetitive NMDA receptor antagonists with features of “improved magnesium” (voltage dependence, affinity) attenuated the deficit. The more direct proof that memantine can act as a surrogate for magnesium was obtained in LTP experiments under low magnesium conditions. In this case as well, impaired LTP was restored in the presence of therapeutically relevant concentrations of memantine (1 µM).In vivo, doses leading to similar brain/serum levels produce neuroprotection in animal models relevant for neurodegeneration in Alzheimer’s disease such as neurotoxicity produced by inflammation in the NBM or β-amyloid injection to the hippocampus. Hence, we postulate that if in Alzheimer’s disease overactivation of NMDA receptors occurs indeed, memantine would be expected to improve both symptoms (cognition) and slow down disease progression because it takes over the physiological function of magnesium.Keywords
This publication has 68 references indexed in Scilit:
- Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ In hippocampal slicesNeuropharmacology, 1999
- Antiglutamatergic therapy in Alzheimer's disease - effects of lamotrigineJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1998
- NMDA antagonist blockade of AT8 tau immunoreactive changes in neuronal culturesFundamental & Clinical Pharmacology, 1996
- Amyloid β Peptide (25–35) Inhibits Na+‐Dependent Glutamate Uptake in Rat Hippocampal Astrocyte CulturesJournal of Neurochemistry, 1996
- The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalisNeuroReport, 1996
- β-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampusNeuroReport, 1995
- Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brainNeurochemistry International, 1995
- Inhibition of Glutamate‐induced Neurotoxicity by a Tau Antisense Oligonucleotide in Primary Culture of Rat Cerebellar Granule CellsEuropean Journal of Neuroscience, 1995
- The Ca2+ influx induced by β‐amyloid peptide 25–35 in cultured hippocampal neurons results from network excitationJournal of Neurobiology, 1995
- Excitotoxity and the NMDA receptorTrends in Neurosciences, 1987